Hyper-CVAD/MA方案治疗15例高度侵袭性非霍奇金淋巴瘤临床观察  

Clinical observation of Hyper-CVAD/MA regimen for 15 highly invasive non-Hodgkin's lymphoma cases

作　　者：曹永峰[1] 宋诸臣[1] 徐小红[1] 杨磊[1] 

机构地区：[1]江苏省南通市肿瘤医院肿瘤内科,江苏南通226361

出　　处：《现代肿瘤医学》2011年第12期2533-2535,共3页Journal of Modern Oncology

摘　　要：目的:观察Hyper-CVAD/MA方案治疗高度侵袭性非霍奇金淋巴瘤的疗效和不良反应。方法:对15例高度侵袭性非霍奇金淋巴瘤患者采用Hyper-CVAD/MA方案治疗:Hyper-CVAD方案:环磷酰胺300 mg/m2静脉注射,每日两次,d1-d3;长春新碱1.4mg/m2,静脉注射,d4、d11;吡柔比星50mg/m2,静脉输注,d4;地塞米松40mg,静脉滴注d1-d4、d11-d14。MA方案:氨甲喋呤1.0g/m2,持续静脉滴注24h,d1;阿糖胞苷1.0g/m2,静脉滴注,每12小时1次,d2-3。结果:15例患者中,总有效率为73.3%,其中CR 7例(46.7%),PR4例(26.6%),随访1年无进展生存率(PFS)为66.7%,1年总生存率(OS)为80.0%。不良反应主要为化疗相关的骨髓抑制。结论:Hyper-CVAD/MA方案治疗高度侵袭性非霍奇金淋巴瘤近期疗效满意,治疗相关不良反应易于控制。Objective：To investigate the clinical curative effect and adverse reaction of hyper-CVAD/MA regimen for highly invasive non-Hodgkin＇s lymphoma.Methods： Fifteen highly invasive non-Hodgkin＇s lymphoma cases were treated with hyper-CVAD/MA regimen.Hyper-CVAD regimen： cyclophosphamide 300 mg/m^2,iv,twice daily on d1 to d3,vincristine 1.4 mg/m^2,iv on d4 and d11,pirarubicin 50 mg/m^2,iv,on d4,dexamethasone 40 mg,iv gtt on d1 to d4 and d11 to d14;MA regimen： methotrexate 1.0 g/m^2 iv gtt continuing 24 h on d1 and cytarabine 1.0 g/m^2 q12h iv gtt on d2 to d3.Results： In 15 cases,the overall response rate was 73.3%.There was a complete response in 7 cases（46.7%）,partial response in 4 cases（26.6%）.The progress free survival（PFS） rate of 1 year follow-up was 66.7%;the overall survival（OS） rate was 80.0%.The most common adverse reaction was bone marrow suppression.Conclusion： Hyper-CVAD/MA regimen can achieve a satisfactory result in the treatment of highly invasive non-Hodgkin＇s lymphoma,and the correlated complications can be controlled easily.

关 键 词：前体淋巴母细胞淋巴瘤 BURKITT淋巴瘤 Hyper-CVAD/MA方案 化疗 

分 类 号：R733.1[医药卫生—肿瘤]